K6Q0 Stock Overview
A biotech company, develops therapies to prevent the metastatic process. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
WntResearch AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.08 |
| 52 Week High | SEK 1.38 |
| 52 Week Low | SEK 0.42 |
| Beta | 0.56 |
| 11 Month Change | 0% |
| 3 Month Change | 0.94% |
| 1 Year Change | 45.27% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| K6Q0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | 45.3% | -17.2% | 8.2% |
Return vs Industry: K6Q0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: K6Q0 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| K6Q0 volatility | |
|---|---|
| K6Q0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: K6Q0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine K6Q0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | Per Goran Norlen | www.wntresearch.com |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
WntResearch AB Fundamentals Summary
| K6Q0 fundamental statistics | |
|---|---|
| Market cap | €501.57k |
| Earnings (TTM) | -€3.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs K6Q0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K6Q0 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 44.02m |
| Earnings | -SEK 44.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did K6Q0 perform over the long term?
See historical performance and comparison